Poseida Therapeutics Presents Clinical Manufacturing Method for Durable, Persistent CAR-T Stem Cell Memory Therapies at World Orphan Drug Congress USA

SAN DIEGO, April 26, 2018 (GLOBE NEWSWIRE) — Poseida Therapeutics Inc., a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, provided an overview of its non-viral piggyBac™ DNA Modification System at the World Orphan Drug Congress USA 2018. PiggyBac is a proprietary gene insertion technology used for the development of gene and CAR-T therapy product candidates in Poseida’s pipeline, including P-BCMA-101, currently in Phase 1 clinical development for the treatment of multiple myeloma.